Alfons J.M. van den Eertwegh
Amsterdam UMC Location University of Amsterdam · 302 works · 27,278 citations · h-index 60
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
- A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
- Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
- Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression
- Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage
- Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation
- Immunological functions and in vivo cell-cell interactions of T cells in the spleen.